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ABSTRAK
Penggantian cecair adalah rawatan utama untuk kencing manis ketoacidosis 
(DKA). Pada masa ini pilihan terbaik daripada cecair masih diperdebatkan. 
0.9% Normal Saline (NS) yang menyebabkan ketidakseimbangan metabolik 
dan asidosis metabolik biasanya digunakan. Sterofundin® merupakan kristaloid 
alternatif yang dianggap mempercepatkan resolusi asidosis. Kelebihan dalam 
kandungan sterofundin adalah perbezaan kecil besar ion (SID) kepada plasma 
dan kandungan klorida yang lebih rendah. Objektif utama kajian ini adalah 
untuk membandingkan kadar resolusi asidosis dalam pesakit DKA antara rawatan 
dengan 0.9% saline normal dan Sterofundin® dalam 12 jam. Objektif lain adalah 
untuk membandingkan perbezaan yang signifikan ion (SID),12 jam pelepasan 
keton darah dan keseimbangan elektrolit antara kedua-dua kumpulan. Kajian ini 
adalah kajian terbuka dilabel percubaan trial kawalan rawak. Kajian ini dijalankan 
selama 6 bulan. Saiz sampel sebanyak 18 orang telah diperolehi dan (n = 9) 
untuk setiap lengan. Perbezaan utama antara kedua-dua kumpulan adalah awal 
median 2 jam peningkatan tahap pH (NS = +0.006 vs Sterofundin = +0.05, P = 
0.063), bagaimanapun tidak ketara. Keton, pengurangan jurang anion, normalisasi 
bikarbonat, sodium, klorida, urea dan tahap kreatinin gagal menunjukkan 
sebarang perbezaan yang signifikan antara kedua-dua kumpulan. Dua belas jam 
paras klorida median kenaikan adalah lebih tinggi dalam kumpulan NS (+11) 
berbanding dengan kumpulan sterofundin yang (+6). Tidak ada perbezaan antara 
kematian dan morbiditi. Perbandingan kedua-dua kumpulan cecair, tidak terdapat 
perbezaan biokimia penting sepanjang rawatan DKA. Ini adalah kajian pilot yang 
memerlukan trial klinikal yang lebih besar di masa akan datang.
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(Malaysian Clinical Practice Guidelines 
2015).
 The ideal fluid for managing 
diabetic ketoacidosis (DKA) is 
controversial. Following substantial 
fluid loss due to osmotic diuresis, fluid 
deficit can be estimated up to 100 ml/
kg which is corrected within 24 hrs. 
Crystalloid 0.9% normal saline (NS) 
is currently the mainstay therapy for 
fluid replacement. Fluid replacement 
regiment for a systolic BP > 90 mmHg 
is 1000 mL of NS for the 1st hr, another 
1000 mL of NS for next 2 hrs and 1000 
Kata kunci: jurang anion, diabetic ketoacidoses, keton, ph , saline, sterofundin
ABSTRACT
Fluid replacement is the mainstay treatment for diabetic ketoacidosis (DKA). 
Currently, the best choice of fluids is still debatable. An amount of 0.9% sodium 
chloride is commonly used. Sterofundin® is an alternative crystalloid that is 
assumed to expedite resolution of acidosis. Advantages in sterofundin content 
being smaller significant ion difference (SID) to plasma and lower chloride content. 
The main objective of the study was to compare rate of acidosis resolution in DKA 
patients between treatment with 0.9% normal saline and Sterofundin over 12 hrs. 
Other objectives were to compare significant ion difference (SID), 12-hr blood 
ketone clearance and electrolyte balance between the two groups. The study was 
a prospective open labelled randomized control trial. This study was conducted 
over 6 months. Sample size of 18 was obtained with 9 for each arm. Main difference 
between two groups was initial median 2-hr pH level improvement (NS = +0.006 
vs. Sterofundin = +0.05, P=0.063), however not being significant. Ketone, anion 
gap reduction, bicarbonate normalisation, sodium, chloride, urea and creatinine 
levels failed to show any significant differences between both groups. Twelve-hour 
median chloride levels increments were higher in the NS group (+11) compared 
to the sterofundin group (+6). There was no difference between mortality and 
morbidity. Comparing the two fluid groups, there was no significant biochemical 
differences during treatment of DKA. This was a pilot study that can initiate further 
clinical trials.
Keywords: anion gap, diabetic ketoacidosis, ketone, ph, saline, sterofundin
 
INTRODUCTION
Diabetic ketoacidosis (DKA) is among 
the most serious acute complications 
of diabetes. It is diagnosed these 
criteria are met; elevated capillary 
blood glucose (> 11 mmol/L), elevated 
capillary ketones (> 3 mmol/L) or > 2+ 
positive urine ketones and venous pH 
< 7.3 and/or bicarbonate < 15 mmol/L. 
Management principles include initial 
fluid and potassium replacement, 
intravenous insulin infusion, intensive 
monitoring and targeted investigation 
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mL for the remaining 4 hrs (Malaysian 
Clinical Practice Guidelines 2015). 
 Efficacy of NS in resolving metabolic 
acidosis compared to other crystalloids 
is questionable. High chloride content, 
low strong ion difference (SID) and 
high hydrogen ion levels are among 
factors that can delay metabolic 
acidosis resolution following normal 
saline infusion (Yunos et al. 2010; 
Waters et al. 1999; Waters et al. 2001; 
Reid et al. 2003; Scheingraber et al. 
1999). The effect is compounded 
when a large amount of normal saline 
is used in the treatment of DKA. Strong 
ion difference (SID) is defined as the 
difference between strong cations (Na, 
K, Mg, and Ca) and strong anions (Cl- 
and lactate). 
 An alternative to normal saline is 
balanced solution such as sterofundin, 
ringers lactate, hartmann and 
plasmalyte. These solutions have 
electrolyte composition and SID 
near similar to plasma (Guidet et al. 
2010). The likelihood of developing 
hyperchloraemia is less compared to 
normal saline. This study was designed 
to compare the rate of acidosis 
resolution between normal saline and 
a balanced solution.  Sterofundin as a 
balanced solution was selected due 
to its affordability, availability and 
absence of lactate.  It also had the 
lowest SID (29) and low CO2 content 
(1.5/L) compared to other balanced 
solution (Langer et al. 2014).
MATERIALS AND METHODS
Ethical approval was obtained before 
conductance of the study (Project 
Code: FF-2015-128) and registered 
under the National Medical Research 
Register (NMRR), allowing the study 
to be done in the hospital. General 
objective of this study was to compare 
rate of acidosis resolution between 
infusing NS and Sterofundin in 
DKA patients within 12 hrs. Specific 
objectives were to measure patient’s 
significant ion difference, blood ketone 
and electrolytes (sodium, potassium, 
chloride, magnesium and calcium) in 
both groups within 12 hrs of treatment. 
 The study was designed as a 
prospective open labelled randomized 
control trial. Sterofundin was used for 
fluid replacement therapy compared 
to the standard therapy of NS in DKA 
patients. The study was conducted 
over six months from 1st June 2015 
to 30th December 2015. Recruitment 
of patients was made from the initial 
presentation to the emergency 
department, after criteria of DKA was 
met. Patients who were included 
fulfilled the criteria of DKA according 
Malaysian Clinical Practice Guidelines 
which were adapted from Gosmanov 
et al. (2014). The diagnostic criteria 
were: capillary blood glucose more 
than 11 mmol/L, capillary ketones 
more than 3 mmol/L or urine ketones 
2+ and venous pH less than 7.3 and/
or bicarbonate less than 15 mmol/L. 
Patients who were administered more 
than 500 ml other intravenous fluids 
or 50 mL of sodium bicarbonate 
within 24 hrs, less than 18 yrs of age 
or complicated with congestive heart 
failure or end stage renal failure were 
excluded from this study. Statistical 
analysis was done using IBM SPSS 
version 22.0.0 
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management protocol was monitored 
by emergency physician on duty. DKA 
monitoring chart was available to 
physicians as a guide in blood taking 
and monitoring. 
OUTCOME MEASURES
Venous blood gas (VBG) for pH, 
Bicarbonate, Base Excess, Capillary 
and laboratory glucose, Renal profile 
(RP), Full Blood Count (FBC), Calcium, 
Albumin, Magnesium, Phosphate were 
taken during time of diagnosis. Serial 
blood investigation for VBG, blood 
ketone and RP was repeated at 2, 4, 
8 and 12 hrs. The patient was studied 
until acidosis resolution was complete.
 The mean changes of pH, 
bicarbonate, blood ketone, SIDs, 
Anion Gap, Chloride and Sodium was 
measured over time and compared 
between the two group using student 
t-test to measure statistical difference. 
The protocol and the monitoring chart 
were identified by research ID. No 
personal details were available on 
the forms to protect the privacy and 
confidentiality. The subject was not 
given access to personal information 
and study data. The study data was 
kept for 5 yrs in online storage solution 
which was protected by industry 
standard security. The medical record 
was kept by the hospital as per hospital 
protocol. 
RESULTS 
The study was conducted for six 
months from 1st June 2015 and 30th 
December 2015. Data was collected 
from Hospital Kuala Lumpur and 
STATISTICAL ANALYSIS
The sample size was calculated 
using a general purpose statistical 
software (STATA). The sample size 
was estimated using a two sample 
comparison population of n total= 70. 
Sixty percent of acidosis resolution 
rate within the 6-12-hr period was 
expected from the normal saline group 
in comparison to 80% from sterofundin 
group. Test Ho: p1 = p2, where p1 was 
the proportion in population 1 and 
p2 was the proportion in population 
2. Assumptions area were as follows: 
alpha = 0.0500 (two-sided), power = 
0.9000, p1 = 0.6000, p = 0.2000, n2/n 
= 1.00. Estimated required sample 
sizes: (n1= 35, n2 = 35). Unfortunately, 
we did not manage to reach the 
targeted sample size due to certain 
limitations. Hence, the study became 
a pilot study. 
TREATMENT
Treatment protocols were adopted 
from the Joint British Diabetes Societies 
in Patient Care Group the Management 
of Ketoacidosis in Adults (Savage et 
al. 2011) and the Malaysian Clinical 
Practice Guidelines 2015 (Appendix 
1).  The study flow diagram was shown 
in Figure 1 and the DKA monitoring 
chart was shown in Appendix 2. The 
crystalloid used was randomizing 
between 0.9% normal saline and 
Sterofundin and the timing and blood 
investigations was modified for the 
purpose of the study. Randomization 
was based on the label sealed in 
a brown envelope attached to the 
treatment protocol. Adherence to DKA 
183
Comparing Sterofundin to Normal Saline in Managing DKA Med & Health Dec 2017;12(2): 179-192
Universiti Kebangsaan Malaysia 
Medical Centre. Thirty patients were 
eligible for this study. Five patients were 
excluded because refusal of consent. 
Seven patients were excluded from 
the study because of non adherence 
to the protocol. Only 9 patients were 
obtained for each group. 
DEMOGRAPHICS
The demographic of the patient is 
shown in Table 1. The samples were 
homogeneous between the two 
groups. There was no significant 
difference between the 2 groups in 
terms of baseline characteristics and 
initial blood parameter values. The 
mean total insulin, fluid and urine 
output for the 12 hrs were similar 
between the 2 groups.
THE ACID BASE STATUS AND 
ELECTROLYTES
The median changes of all blood 
parameters monitored over 12 hrs 
were shown in Table 2. The most 
significant difference between the two 
groups was pH increment within the 
first two hrs. Sterofundin showed an 
impressive median improvement of 
0.05, whereas the NS group showed 
slight fall of 0.01 in median pH. There 
was no significant difference in SIDs, 
ketone clearance, anion gap reduction 
Figure 1: Study flow diagram
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and bicarbonate increment between 
the two groups over 12 hrs. There was 
no significant difference in potassium, 
sodium, urea and creatinine levels for 
both groups. However, as expected, 
chloride level in the NS group had 
an increase in trend compared to the 
Sterofundin group. 
Table 1: Baseline characteristics and blood parameters 
Characteristics Normal Saline(n=9)
Sterofundin
(n=9) p Value
Age 46.22 (28 – 73) 44.67 (22 -58) 1.000
Sex
   Male 4(44.4) 6 (66.7) 0.317
   Female 5(55.6) 3 (33.3) 0.480
Pulse rate 126.3 (98 – 145) 103.89 (70 -144) 0.077
Blood pressure
   SBP 125.9 (96 -158) 123.3 (94 – 150) 0.605
   DBP 77.0 (56 – 90) 74.1 (53 – 96) 0.297
Respiratory rate 22.2 (18 -28) 19.9 (16 -24) 0.136
SPO2 (%) 99.00 (98 -100) 99 (95-100) 0.370
GCS 13.7 (3 – 15) 15 (15 -15) 0.730
Random Blood Glucose 29.2 (18.3 -43.0) 28.2 (11.7 – 52.0) 0.796
pH 7.162 (7.000 – 7.243) 7.191 (7.070 – 7.318) 0.340
HCO3 10.6 (6.8 – 16.0) 12.1 (7.9 -17.3) 0.489
Blood Ketone 5.18 (3-7) 6.96 (5-8) 0.019
Na 132.4 (121-142) 131.67 (118 – 144) 1.000
Cl 94.4 (76.0 – 114.0) 96.2 (72.0 -112.0) 0.546
Potassium 4.98 (3.5 – 6.9) 4.58 (3.0 – 6.1) 0.436
Urea 10.2 (6.4 – 20.0) 10.2 (1.2 – 33.9) 0.113
Creatinine 108.3 (28.0 -226.5) 160.7 (54.0 – 385.0) 0.387
Lactate 3.78 (1.40 -8.78) 3.12 (1.00 -7.30) 0.297
WCC 16.9 (7.5 – 33.8) 13.8 (6.4 -28.4) 0.436
Hb 14.5 (11.3 – 18.0) 14.4 (10.0 -16.8) 0.931
Plt 293.1 (160 – 418.0) 277.9 (192.0 – 487.0) 0.666
Ca 2.29 (1.92 – 3.14) 2.23 (1.95 - 3.14) 0.796
Alb 32.89 (22.0 – 48.0) 33.54 (3.9 – 47.0) 0.546
Mg 1.04 (0.70 – 2.54) 0.95 (0.70 – 1.90) 0.863
Phos 1.34 (0.50 – 2.54) 1.09 (0.60 – 1.74) 0.387
Total Insulin (ml) 56.5 (40.0-87.0) 56.00 (18-81.5) 0.370
Total Fluid (ml) 4639.50 (2286 – 7853) 4898.3 (3000 – 6120) 0.888
Total Urine output (ml) 1540.00 (660 -12000) 1150.00 (800 -1750) 0.139
Infection (%) 9/9 (100) 6/9 (66.7)
Non compliance 0/9 (0) 3/9 (11.1)
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Table 2: Blood parameter changes in 12 hours 
Variables Time points Normal salineMedian (IQR)
Sterofundin
Median (IQR) P value
D in pH 0 0.00 (0-0) 0.00 (0-0) 1.000
2 -0.006 (-0.343-0.104) 0.050 (-0.343 – 0.104) 0.063
4 0.063 (-0.127 – 0.166) 0.050 (0.009 – 0.248) 0.436
8 0.143 (-0.007 – 0.259) 0.143 (0.091 – 0.276) 0.796
12 0.157 ( 0.115 – 0.279) 0.192 ( 0.065 – 0.289) 0.863
D in anion gap 0 0.00 (0-0) 0.00 (0-0) 1.000
2 -1.50 (-10 – 11) -4.8 (-17 – 16) 0.258
4 -12.4 (-20 – 3) -6.6 (-18 – 13) 0.666
8 -14.1 (-24 – 7) -10.2 ( -33 – 4) 0.730
12 - 16.0 ( -24 – 3) -11.7 (-27 – 3) 0.863
D in blood ketone 0 0.00 (0-0) 0.00 (0-0) 1.000
2 -0.80 (-2 – 3) -0.60 (-4 - 1) 0.931
4 -1.80 (-4 – 3) - 2.50 ( -6 - 0) 0.258
8 -2.30 (-6 - 2) - 4.00 ( -7 - -1) 0.077
12 -3.70 (- 7 - 0) -4.70  (-8 - -4) 0.113
D in bicarbonate 0 0.00 (0-0) 0.00 (0-0) 1.000
2 0.40 (-2 – 4) 1.10 ( -3 -4 ) 0.340
4 3.30 (1 -12) 2.30 (-4 - 9) 0.730
8 5.50 (2- 15) 5.70 (2- 10) 0.931
12 5.10 (3 -15) 8.20 (2- 13) 0.297
 Strong ion gap 0 0.00 (0-0) 0.00 (0-0) 1.000
2 -1.50 (-10 11) - 4.8 (-17 – 16) 0.258
4 -12.4 (-20 -3) -6.60 (-18 -13) 0.666
8 -14.1 (-24 -7) -10.2 (-33 -4) 0.730
12 -16.0 (-24 -3) -11.7 (-27 -3) 0.863
D in potassium (mmol) 0 0.00 (0-0) 0.00 (0-0) 1.000
2 -0.3 (12 – 0) -0.6 (-2 -1) 0.730
4 -0.6 (-3 -1 ) -0.3 (-5 -3) 0.546
8 -1.0 (-3 -0) -0.8 (-2 -1) 0.796
12 -1.2 (-3 -0) -1.1 (-3 -0) 0.863
D in chloride 0 0.00 (0-0) 0.00 (0-0) 1.000
2 3.0  (-5 - 15) 6.0 (-5 – 30 ) 0.546
4 9.0 (-11 - 23) 3.0 (-7 -31) 0.666
8 12.0 ( -22 - 33) 2.0 (-8 -36) 0.436
12 11.0 ( -10 -26) 6.0 (-7 -43) 0.931
D Sodium 0 0.00 (0-0) 0.00 (0-0) 1.000
2 1.0 (-1 - 15) 2.0 (0 – 18) 0.436
4 2.0 (-6 - 14) 1.0 (-1 - 18) 0.931
8 2.0 (-10 - 22) 1.0 (-4 - 12) 0.489
12 0.0 (-10 - 21) 3.0 (-3 - 27) 0.222
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MORTALITY AND MORBIDITY
Morbidity and mortality of the study is 
shown in the Table 3. There was one 
death at discharge in the Sterofundin 
group. Patient deteriorated three days 
after admission and was intubated 
and required inotropic support. Cause 
of death was sepsis secondary to 
urinary tract infection.  There was no 
significant difference in mortality and 
morbidity in between the two groups.
DISCUSSION
There was a notable difference in 
the initial biochemical parameters 
between both groups. The pH in 
Sterofundin group showed a steady 
increase compared to normal saline 
(Table 2). There was a difference in the 
change of median pH (-0.006 vs 0.05) 
within the first two hrs. Development 
of hyperchloremic acidosis from 
substantial infusion of normal saline 
explained these results. Nevertheless, 
range of results in both groups remains 
the same (-0.343 – 0.104). Physiological 
compensatory mechanism normalized 
the chloride and pH levels over time.  
Reduction in anion gap was also 
higher in the sterofundin group. 
 Ketone clearance occured more 
rapidly in the sterofundin group. 
Sterofundin does not cause increase 
in chloride content in the blood. Both 
group increased the bicarbonate and 
reduces of anion gap and significant 
ion difference over time. This was 
similar to the study on plasmalyte 
by Chua et al. (2012) in which the 
balanced solution resulted in rapid 
acidosis resolution and lower chloride 
levels. 
 Although, there was added 
potassium in Sterofundin, the 
potassium level in the Sterofundin 
group remained the same compared 
to the other group. In addition to this, 
continuous infusion of insulin reduced 
intracellular potassium level. This study 
showed that it is safe to use Sterofundin 
in DKA patient who has no renal 
failure. Sterofundin in DKA does not 
increase the potassium level in serum. 
On the other hand, it will pose benefits 
in preventing hypokalemia. It will be 
cost effective as the need of repleting 
potassium is not needed. 
 These findings are similar to the 
study done by Chua et al. (2012) 
and Mahler et al. (2011). Plasmalyte 
was used as the balanced fluid 
which caused less hyperchloremic 
acidosis compared to normal saline. 
Sterofundin has lower SID than 
Plasmalyte which can explain a higher 
significant effect on the biochemical 
Table 3: Mortality and morbidity
Normal Saline Sterofundin
Mortality (%) 0/9 (0) 1/9 (11.1)
None (%) 9 (100) 8/9  (88.9)
Renal replacement (%) 0/9 (0) 1/9 (11.1)
Pulmonary edema (%) 0/9 (0) 0/9 (0)
Hyperkalemia (%) 0/9 (0) 0/9 (0)
Others (%) 0/9 (0) 0/9 (0)
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outcome. Plasmalyte has a SID of 54 in 
comparison to Sterofundin which has 
a SID of 29 and is closer to plasma. 
However, similar to their study, SID 
of patients was same in both groups. 
There was no difference for patients 
who underwent renal replacement 
therapy and these findings was similar 
to SPLIT trial (Young et al. 2015).
 There is inadequate evidence at 
the moment to change the current 
recommendation in treating DKA. This 
study was introduced to the Emergency 
Department as an alternative protocol 
in managing DKA patients. The variable 
scale insulin infusion was more widely 
use before the implementation of the 
study although the fix scale insulin 
infusion was recommended by the 
British guideline since 2013. With use 
of integrated monitoring chart, the 
monitoring of the patient and serial 
timing of blood taking was more 
standardized. The record of blood 
ketone clearance could be emphasized 
by charting the reduction on a single 
page along with other important 
parameters such as potassium level, 
fluid rate and urine output. This helps 
the clinician to visualize the progress 
of the patient’s serial biochemical 
parameters. 
 Small sample size was the main 
limitation of this study. One of the 
causes was poor adherence towards 
the implemented DKA sterofundin 
protocol. Once participant was 
admitted to medical ward, the fluid 
infused was changed to normal saline. 
This was mainly due to unfamiliar and 
unwilling practitioner in adhering to 
the protocol. Further education and 
thorough briefing should be done 
to all specialities involved in this 
study. This small sample size resulted 
in inadequate power to show any 
statistical difference and variability in 
the data between the 2 groups. An 
extension of the study is needed in 
order to recruit more patients. 
 Time length of each individual 
study was only 12 hrs due to logistic 
consideration and financial constraint. 
The time was not enough to look at 
full resolution of acidosis and ketone 
clearance. This should be extended to 
24 hrs in order to see the full effect.  
CONCLUSION
Generally, with a limited sample size 
there was a noticeable difference 
between patients treated with 
sterofundin and normal saline for 
DKA. As this can be considered as a 
pilot study, it can pave way to more 
clinical trials in the future. There 
was earlier acidosis reversal, rapid 
reduction of anion gap and prevention 
of potassium depletion after with 
sterofundin infusion. This study can 
act as a platform for further studies in 
order to obtain significant outcome 
and change our current management 
of DKA patients.
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Appendix 1: DKA Protocol Guidelines (Malaysian CPG 2015)
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Appendix 2: HKL Adult DKA Management Chart
